Stock RXO RXO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus RXO, Inc.

Equities

RXO

US74982T1034

Real-time Estimate Cboe BZX
Other stock markets
 02:24:43 2024-05-08 pm EDT 		5-day change 1st Jan Change
20.6 USD -0.58% Intraday chart for RXO, Inc. +8.32% -11.52%
May. 02 RXO Swings to Q1 Loss as Revenue Falls; Shares Rise MT
May. 02 Transcript : RXO, Inc., Q1 2024 Earnings Call, May 02, 2024

Evolution of the average Target Price on RXO, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a.QJU90IsTDE1qIJwxAW1q1B0NL36laoesCD6yHjWTMeI.N8AItNpaXhJfd9AGVQEMrFhcfSbNKbfvcmuHeBjmVJZwxATm5XBWdTpz3Q~05eab1e3490320e9fdd0163c0cf06b23

Analyst Recommendations on RXO, Inc.

Susquehanna Raises RXO Price Target to $16 From $15, Maintains Negative Rating MT
Oppenheimer Trims RXO Price Target to $22 From $23, Maintains Outperform Rating MT
UBS Adjusts RXO Price Target to $22 From $20, Maintains Neutral Rating MT
Susquehanna Adjusts Price Target on RXO to $15 From $18, Maintains Negative Rating MT
BofA Securities Adjusts Price Target on RXO to $25 From $21, Maintains Buy Rating MT
Stifel Adjusts RXO's Price Target to $22 From $20, Maintains Hold Rating MT
Vertical Research Downgrades RXO to Hold From Buy, Trims Price Target to $23 From $24 MT
Oppenheimer Adjusts RXO Price Target to $23 From $20, Maintains Outperform Rating MT
UBS Adjusts RXO Price Target to $20 From $21, Maintains Neutral Rating MT
Oppenheimer Adjusts RXO Price Target to $20 From $24, Maintains Outperform Rating MT
JPMorgan Downgrades RXO to Underweight From Neutral, Trims Price Target to $16 From $17 MT
Morgan Stanley Adjusts RXO's Price Target to $18 From $20, Keeps Equalweight Rating MT
Susquehanna Downgrades RXO to Negative From Neutral, Adjusts Price Target to $14 From $19 MT
Goldman Sachs Adjusts Price Target on RXO to $21 From $20, Maintains Neutral Rating MT
UBS Adjusts RXO Price Target to $21 From $23, Maintains Neutral Rating MT
Stephens Adjusts Price Target on RXO to $19 From $21, Maintains Equal-Weight Rating MT
Goldman Sachs Adjusts Price Target on RXO to $20 From $21, Maintains Neutral Rating MT
Wolfe Research Downgrades RXO to Underperform From Peer Perform, Sets $18 Price Target MT
Susquehanna Initiates RXO at Neutral With $20 Price Target MT
Barclays Initiates RXO at Overweight Rating With Price Target $27 MT
Analysis-US retailer holiday orders should boost transport demand, but risks loom RE
Wells Fargo Adjusts Price Target on Buy Now to $21 From $22, Maintains Equalweight Rating MT
Goldman Sachs Adjusts Price Target on RXO to $21 From $22, Maintains Neutral Rating MT
Benchmark Initiates RXO at Hold MT
Cowen Initiates Coverage on RXO With Market Perform Rating, $22 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
15
Last Close Price
20.72 USD
Average target price
20 USD
Spread / Average Target
-3.47%
High Price Target
25 USD
Spread / Highest target
+20.66%
Low Price Target
13 USD
Spread / Lowest Target
-37.26%

Consensus detail

Consensus revision (last 18 months)

Analysts covering RXO, Inc.

Susquehanna
Oppenheimer
UBS
BofA Securities
Stifel Nicolaus
Vertical Research
JPMorgan Chase
Morgan Stanley
Goldman Sachs
Stephens Inc.
Wolfe Research
Barclays
Wells Fargo Securities
Benchmark Company
Cowen
Jefferies & Co.
Raymond James

Ratings for RXO, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. RXO Stock
  4. Consensus RXO, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW